The Association of the Epidermal Growth Factor Receptor (EGFR) Immunoexpression With Prognostic Parameters in Adenocarcinoma Patients Receiving Neoadjuvant Treatment

Simple item page
dc.contributor.authorDemir, D
dc.contributor.authorParvizi, M
dc.contributor.authorPehlivanoglu, B
dc.contributor.authorErgin, E
dc.contributor.authorAyhan, S
dc.contributor.authorDoganavsargil, B
dc.date.accessioned2024-07-18T12:01:15Z
dc.date.available2024-07-18T12:01:15Z
dc.description.abstractThe epidermal growth factor receptor (EGFR) expression is considered to play an essential role in the pathogenesis of colorectal adenocarcinoma. This study assessed the expression and predictive/prognostic value of EGFR expression in pre -op biopsy and post -op resection specimens in patients receiving neoadjuvant radiotherapy/neoadjuvant chemoradiotherapy (NRT/NCRT). Thirty-four consecutive patients were included in this study. The association between the prognostic features and EGFR immunohistochemical expression was analyzed in pre- (n=34) and post -treatment (n=22) tissue samples in cases with available tissue blocks. Of 34, 23 (67.6%) were men. The median age was 60.50 +/- 10.69 (range, 31-84) years. EGFR expression was detected in 88.2% of biopsy specimens and in 91.2% of surgical specimens. There was only slight agreement between pre -op and post -op EGFR expression scores (kappa value 0.11). There was no significant correlation between pre -op and post -op EGFR expression scores (p>0.05). Although pre -op EGFR positivity and higher pre -op EGFR scores seemed to indicate a worse prognosis, this association between pre -op EGFR expression and overall survival (OS) or disease -specific survival (DSS) did not reach statistical significance (p>0.05). The only case with a post -op EGFR score of three who died of the disease experienced local recurrence and had distant metastasis. In conclusion, EGFR positivity in pre -op biopsy samples seems to be associated with shorter survival, and increased EGFR expression in post -treatment resection specimens predicts aggressive behavior in patients with rectal adenocarcinoma who received NRT/NCRT. However, due to the molecular heterogeneity, EGFR expression status should be evaluated in resection specimens rather than in pre -op biopsy samples for optimal prognosis prediction.
dc.identifier.other2168-8184
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/8279
dc.language.isoEnglish
dc.publisherSPRINGERNATURE
dc.subjectRECTAL-CANCER
dc.subjectPROTEIN OVEREXPRESSION
dc.subjectGENE AMPLIFICATION
dc.subjectCOLORECTAL-CANCER
dc.subjectFOLLOW-UP
dc.subjectEXPRESSION
dc.subjectCARCINOMAS
dc.titleThe Association of the Epidermal Growth Factor Receptor (EGFR) Immunoexpression With Prognostic Parameters in Adenocarcinoma Patients Receiving Neoadjuvant Treatment
dc.typeArticle

Files

Collections

Web of Science Koleksiyonu